Singapore Healthcare Contract Research Organization Market Size, Share, and COVID-19 Impact Analysis, By Type (Pre-Clinical, and Clinical), By Therapeutic Area (Oncology, CNS Disorders, Infectious Diseases, Immunological Disorders, and Cardiovascular Disease), By End User (Pharmaceutical Companies, Medical Device Companies, and Academic Institutes), and Singapore Healthcare Contract Research Organization Market Insights, Industry Trend, Forecasts to 2035

Singapore Healthcare Contract Research Organization Market Insights Forecasts to 2035

• The Singapore Healthcare Contract Research Organization Market Size Was Estimated at USD 703.67 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 10.7% from 2025 to 2035
• The Singapore Healthcare Contract Research Organization Market Size is Expected to Reach USD 2152.16 Million by 2035

According to a research report published by Spherical Insights & Consulting, the Singapore Healthcare Contract Research Organization Market size is anticipated to reach USD 2152.16 Million by 2035, growing at a CAGR of 10.7% from 2025 to 2035. The market for healthcare contract research organization in Singapore is mostly driven by increased spending on pharmaceutical R&D, more complicated regulations, and the use of cutting-edge technologies in clinical trials, and the growing demand for new medications and therapies.

Market Overview

The regulatory and IRB review procedures in Singapore are among the most efficient. A 30-day evaluation and approval period is the goal set by Singapore's regulatory Health Sciences authority.

Specialized production services and R&D-intensive manufacturing are the main emphasis of the Biopolis and Mediapolis regions. CTCs from the HSA are still necessary for all clinical trials involving pharmaceuticals carried out in Singapore.  Due to rising R&D costs, rivalry among generic versions of branded drugs, and the expiration of patents on the most lucrative drugs, pharmaceutical companies have been forced to find ways to reduce costs and expedite R&D processes.

The healthcare contract research organization (CRO) industry is growing significantly. CROs provide clinical trial services to a range of companies, including those in the biotechnology, pharmaceutical, and medical device industries. The market is expanding due to the advancement of AI in healthcare contract research organizations. This is due to AI applications in CROs offering a number of advantages, such as better data quality, increased patient safety, and quicker trial completion. Through the provision of resources and expertise without the need for substantial internal infrastructure, CROs reduce operating costs, contributing to market expansion.

Report Coverage

This research report categorizes the market for Singapore healthcare contract research organization market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Singapore healthcare contract research organization market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Singapore healthcare contract research organization market.

Driving Factors

The Healthcare Contract Research Organization Market Size in Singapore is driven by the growing demand for new medications and therapies, collaborations between regional biotech companies and global CROs, emphasis on precision medicine trials that propel specialized CRO services, and the growth of clinical trial sites in Singapore's medical research institutions are all contributing factors to the increased use of digital health technologies in clinical trials.

Restraining Factors

The Singaporean Healthcare Contract Research Organization Market Size is constrained by the high operational expenditures, which include increased expenses for labor, real estate, and operations. In modern pharmaceutical manufacturing, a shortage of specialized technical skills leads to supply chain disruption, complicated regulatory requirements, increased international competitiveness, and manpower limits. 

Market Segmentation

The Singapore healthcare contract research organization market share is classified into type, therapeutic area, and end user.

• The clinical segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Singapore healthcare contract research organization market is segmented by type into pre-clinical and clinical. Among these, the clinical segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The growth of the segment is driven by emphasizing tight budgets and deadlines more and more, which has led to a propensity for hiring CROs for outsourcing or establishing specialized clinical trial labs. In addition, as trials get more complex due to cancer and orphan diseases, which call for creative ways in drug development.

• The oncology segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

The Singapore healthcare contract research organization market is segmented by therapeutic area into oncology, CNS disorders, infectious diseases, immunological disorders, and cardiovascular disease. Among these, the oncology segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth is driven by the rising cancer rate and the urgent need for innovative therapies. The importance of outsourcing to CROs is growing since cancer research requires extensive, complex clinical trials with sophisticated designs, strict adherence to regulations, and patient recruitment. CROs provide advanced technologies, global networks, and specialized knowledge to efficiently manage oncology trials and assist drug development pipelines for targeted medications, immuno-oncology, and precision medicine.

• The pharmaceutical companies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Singapore healthcare contract research organization market is segmented by end user into pharmaceutical companies, medical device companies, and academic institutes. Among these, the pharmaceutical companies segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The growth of the segment is driven by progressively focusing their efforts on research and development, as well as commercialization by offshore, both primary and secondary manufacturing. Medical device firms, especially those creating sophisticated diagnostic and therapeutic gadgets that need Singapore's sophisticated production facilities and governmental proficiency, are becoming an important growth category.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations or companies involved within the Singapore healthcare contract research organization market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Singapore Clinical Research Institutes
• Pheonix Pharma Central Services
• IQVIA Singapore
• PPD Singapore
• Syneos Health Singapore
• Charles River Laboratories Singapore
• Medpace Singapore
• WuXi AppTec Singapore
• Parexel Singapore
• Lonza Singapore
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

In April 2025, Siemens Healthineers and Singapore General Hospital (SGH) signed a Memorandum of Understanding (MOU) to establish a five-year strategic partnership to advance healthcare solutions and support SGH in medical innovation.

In March 2025, Novotech, a recognised full-service biotech specialist clinical research organization (CRO), announced that affiliates of GIC and Temasek had signed binding agreements to acquire a significant stake in the company, with the additional capital earmarked to accelerate its growth.

In January 2025, NVIDIA announced a trio of partnerships with IQVIA, Illumina, and Mayo Clinic and a research collaboration to boost the healthcare sector.

Market Segment

This study forecasts revenue at the Singapore, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Singapore Healthcare contract research organization Market based on the below-mentioned segments:

Singapore Healthcare Contract Research Organization Market, By Type

• Pre-Clinical
•  Clinical

Singapore Healthcare Contract Research Organization Market, By Therapeutic Area

• Oncology
• CNS Disorders
• Infectious Diseases
• Immunological Disorders
• Cardiovascular Disease

Singapore Healthcare Contract Research Organization Market, By End User

• Pharmaceutical Companies
• Medical Device Companies
• Academic Institutes